Candida Yates has been appointed a Founding Scholar of the British Psychoanalytic Council. This is in recognition of her significant contribution to academic research in the area and beyond. The BPC is the professional registration body for the UK’s leading psychoanalytical practitioners. Up until recently, affiliations were open solely to qualified clinicians trained in the practice of psychoanalysis, psychoanalytical psychotherapy, and psychodynamic psychotherapy.
This newly created category expands the BPC’s purview by recognising the enormous contribution that academics and scholars have made to the study of psychoanalysis through research and publication. Being a Founding Scholar can open up further opportunities for debate, collaboration and knowledge exchange between the BPC, academia and beyond. The launch event was held at the Freud Museum in London on 21st February 2019.
As a Founding Scholar, Candida has now been invited to join the new organising committee for BPC Scholars to shape this new and exciting association going forward. She has also been invited to join the Editorial board of their members magazine ‘New Associations’: https://www.bpc.org.uk/new-associations.
BU’s Sascha Dov Bachmann appointed Reviewer to The Estonian Research Council (ETAg)
Conference: Powerplay: Psychoanalysis and Political Culture; BU at the Freud Museum, 10th December










Deadline Approaching: Submit your Poster for the Research Conference by Monday 27 April
BU academics publish in Nepal national newspaper
New BU Physiology paper
Gender and street names
Help Shape the Future of Research at BU: Postgraduate Research Experience Survey 2026 Now Open
3C Event: Research Culture, Community & Cherry Blossom – Tuesday 14 April
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease